COPD Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been admitted to hospital with a flare-up of COPD (a lung condition often caused by smoking) as their main diagnosis
- People who have a smoking history of at least 10 pack years (this is a measure of how much someone has smoked over time — confirm with trial site if unsure how this applies)
- People who have confirmed airflow blockage in their lungs, shown by a specific breathing test result (called FEV1/FVC ratio below 0.7), either from a past test or one done during the hospital stay
- People who are able to understand and agree to take part in the trial by giving informed consent
Who may not be able to join:
- People who have a parasitic infection, a serious fungal infection (not including nail or skin infections), or certain conditions that cause high levels of a type of blood cell called eosinophils (such as eosinophilic granulomatosis with polyangiitis or hypereosinophilic syndrome)
- People who currently have an active cancer
- People who regularly take steroid tablets (such as prednisolone) or other systemic steroids, or who take medications that affect eosinophil levels (including a type of treatment called anti-interleukin 5 therapy)
- People who have poor vein access, making blood draws difficult
- People who have a confirmed history of asthma, as determined by the trial investigator
- People who have other health conditions (unrelated to COPD) that the lead investigator believes could interfere with the study being carried out properly
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Stephen Bourke, MBChB, PhD, Northumbria Healthcare NHS Foundation Trust
Phone: 0191 293 4351
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Indices independently associated with eosinopenia on admission in patients with a severe exacerbation of COPD.; The time taken for BEC to recover to stable state following a severe exacerbation of COPD.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.